IM 101
Alternative Names: IAB-101; IM-101Latest Information Update: 14 Mar 2024
At a glance
- Originator ImmunAbs
- Class Antianaemics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 11 Mar 2024 Phase-I clinical trials in Paroxysmal nocturnal haemoglobinuria (In volunteers) in USA (Parenteral), prior to March 2024
- 11 Mar 2024 Adverse events data from a phase I trial in Paroxysmal nocturnal haemoglobinuria released by ImmunAbs
- 11 Mar 2024 ImmunAbs completes a phase I trial in Paroxysmal nocturnal haemoglobinuria (In volunteers) in USA (Parenteral)